Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year

3 weeks ago 17

Jonathan Ponciano, The Motley Fool

Sun, February 22, 2026 astatine 12:13 PM CST 4 min read

Redmile Group disclosed a important simplification successful its Zymeworks (NASDAQ:ZYME) presumption successful a February 17, 2026, SEC filing, selling an estimated $70.10 cardinal successful shares based connected quarterly mean pricing.

According to a February 17, 2026, SEC filing, Redmile Group reduced its involvement successful Zymeworks by 3,214,096 shares, with the estimated transaction worth totaling $70.10 cardinal based connected the mean closing terms during the 4th fourth of 2025. The quarter-end worth of the presumption decreased by $50.35 million, a effect of some stock income and banal terms movements.

Post-sale, Zymeworks accounts for 0.95% of Redmile’s reportable 13F AUM.
Top holdings aft the filing:
- NASDAQ:SRRK: $229.98 cardinal (16.9% of AUM)
- NASDAQ:KRYS: $167.08 cardinal (12.3% of AUM)
- NASDAQ:NRIX: $153.54 cardinal (11.3% of AUM)
- NASDAQ:STOK: $128.04 cardinal (9.4% of AUM)
- NASDAQ:IMNM: $122.83 cardinal (9.0% of AUM)
As of February 17, 2026, shares of Zymeworks were priced astatine $23.07, up astir 60% implicit the past twelvemonth and outperforming the S&P 500’s astir 13% summation successful the aforesaid period.

Metric

Value

Price (as of marketplace adjacent 2026-02-17)	$23.07
Market Capitalization	$1.74 billion
Revenue (TTM)	$134.48 million
Net Income (TTM)	($63.43 million)

Zymeworks develops and commercializes biotherapeutics for cancer, with pb candidates including zanidatamab (a bispecific antibody successful Phase 1/2 trials) and ZW49 (an antibody-drug conjugate successful Phase 1 trials).
The steadfast operates a clinical-stage biopharmaceutical model, generating gross chiefly done licensing agreements, probe collaborations, and milestone payments from strategical partners.
It targets pharmaceutical companies and healthcare providers focused connected oncology, addressing unmet aesculapian needs successful crab treatment.

Zymeworks is simply a clinical-stage biotechnology institution specializing successful the find and improvement of innovative crab therapies, leveraging a robust pipeline and strategical partnerships with large pharmaceutical firms. The company’s absorption connected bispecific antibodies and antibody-drug conjugates positions it astatine the forefront of targeted oncology therapeutics. Zymeworks’ collaborative concern exemplary and proprietary exertion platforms supply a competitory borderline successful advancing next-generation crab treatments.

When a apical biotech holder cuts a presumption to nether 1% of assets aft a crisp rally, that displacement is worthy noting, peculiarly since Zymeworks entered 2026 with tangible momentum. Positive Phase 3 HERIZON-GEA-01 information for zanidatamab successful first-line HER2-positive gastroesophageal crab showed a statistically important progression-free endurance payment and a median wide endurance exceeding 2 years successful operation therapy. The institution is eligible for up to $440 cardinal successful regulatory milestone payments tied to approvals successful large markets. It besides ended 2025 with astir $270.6 cardinal successful currency and marketable securities, and has a $125 cardinal stock repurchase authorization successful place.

Against that backdrop, trimming into spot looks much similar superior recycling than a nonaccomplishment of faith. This money inactive runs a concentrated biotech portfolio, with double-digit allocations to different objective names.

Shares are up astir 60% implicit the past year, acold outpacing the broader market. Ultimately, however, Zymeworks present sits successful a modulation phase, balancing royalty aggregation, interior R&D, and superior returns, and presumption sizing reflects that evolving hazard profile.

Read Entire Article